ClinicalTrials.gg
CompletedNCT02933320Updated Jul 8, 2021Results posted

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

A Phase 1/2 interventional study of BI-1206 single agent dose escalation phase and Combination of BI-1206 with rituximab escalation phase in B-cell Lymphoma, Chronic Lymphocytic Leukaemia and Waldenström Macroglobulinemia, sponsored by Cancer Research UK. Completed at 5 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-08.

Sponsored by Cancer Research UK · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Lymphoma, B-Cell with a site in United Kingdom — 14 open to participants now, 29 under way, 10 of them phase 3. Lymphoma, B-Cell · United Kingdom.

Enrollment
56th of 59
14 · median 166
Started
2016
with 3 others
Phase 1/2
17 of 64
5 open now
Registered
25th of 64
by date
Lead sponsor
3 of 64
Cancer Research UK

Among the 64 studies in Lymphoma, B-Cell with a site in United Kingdom, this one is the 56th largest by enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2016, is one of 17 in phase 1/2, and was the 25th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

14 of the 64 studies in Lymphoma, B-Cell with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Lymphoma, B-Cell with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this trial is to identify the tolerable dose of BI-1206 (both alone and in combination) for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206 alone and in combination with an anti-CD20 antibody.

Read the detailed description

The molecule CD32b is thought to be present on many B-cells including the malignant B-cells in some types of lymphoma and leukaemia. The study drug, BI-1206, is an anti-CD32b monoclonal antibody which attaches to CD32b on the surface of B-cells and is thought to act by recruiting host immune cells toward the tumour leading to cancer cell death as well as enhancing the anti-cancer effect of other anti-CD20 antibodies such as rituximab by stopping them being absorbed by cells.

The study is a first in man clinical trial of the drug called BI-1206 on its own and then also in combination with an anti-CD20 antibody (such as rituximab) which is commonly used to treat lymphoma and some types of leukaemia.

The four main aims of this trial are to find out:

  • The maximum dose of BI-1206 that can be given safely to patients (to a maximum dose of 800mg) on it's own and in combination with an anti-CD20 antibody, rituximab.
  • More about the potential side effects of BI-1206 and how they can be managed.
  • What happens to BI-1206 inside the body.
  • The effect of BI-1206 treatment (with or without rituximab) on tumour size and survival.

Approximately 81 patients with relapsed or refractory CD32b positive B-cell lymphoma or leukaemia were planned for the trial. Approximately 34 patients to establish the maximum tolerated doses (MTDs) in Part A and a further 40 to 50 patients recruited to two expansion cohorts; one of BI-1206 alone and one of BI-1206 plus rituximab (Part B). The final number depending on the number of dose escalations required to reach the MTD.

03

Conditions studied

  • B-cell Lymphoma
  • Chronic Lymphocytic Leukaemia
  • Waldenström Macroglobulinemia

Keywords

  • Indolent B-cell Lymphoma
  • Chronic Lymphocytic Leukaemia
  • Waldenström Macroglobulinemia
  • BI-1206
  • CD32b
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written (signed and dated) and be capable of co-operating with treatment and follow-up.
  2. B-cell lymphoma or CLL proven by histology or flow cytometry, to conventional treatment, or for which no conventional therapy exists or is declined by the patient. Patients should have received at least one line of conventional previous therapy which must have included a rituximab based regimen.
  3. CD32b positive as demonstrated centrally by immunohistochemistry or flow cytometry prior to study entry. Available tissue or blood must have been taken within six months of study entry.
  4. of at least 12 weeks.
  5. World Health Organisation (WHO) performance status of 0-2 (Appendix 1).
  6. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week before their first dose of mAb (BI-1206 and/or rituximab) as part of this study.

    Laboratory Test Value required

    (Hb) ≥9.0 g/dL (red cell support is permissible)

    (ANC) ≥1.0 x 10\^9/L (or >0.5 x 10\^9/L if due to lymphoma), granulocyte - colony stimulating factor (G-CSF) support is not permissible at screening

    count ≥50 x 10\^9/L (or ≥30 x 10\^9/L if due to malignant involvement of bone marrow)

    Either:

    Serum ≤1.5 x (ULN) unless raised due to Gilbert's syndrome in which case up to 3 x ULN is permissible.

    Or:

    Alanine amino-transferase () and /or aspartate amino-transferase (AST) ≤ 2.5 x ULN unless raised due to malignant hepatic involvement in which case up to 5 x ULN is permissible

    Either:

    Calculated (Cockcroft Gault) ≥30 mL/min (uncorrected value)

    Or:

    Isotope clearance measurement ≥30 mL/min (corrected)

  7. 18 years or over.
  8. B-cell lymphoma patients only: patients has at least one by CT scan (defined as greater than 1.5 cm in one axis) or in the case of Waldenström's macroglobulinemia, disease must be assessable by the criteria stated in Appendix 6 of the protocol.
  9. Patients recruited to Arm 2 in Parts A and B (combination arms) only: CD20 positive malignancy as demonstrated by immunohistochemistry or flow cytometry prior to trial entry.

Exclusion criteria

Exclusion Criteria:

  1. Allogenic bone marrow transplant within 12 months prior to the first dose of BI-1206 or presence of chronic .
  2. Patients with clinically active or central nervous system lymphoma/leukaemia.
  3. Doses of prednisolone >10 mg daily (or equipotent doses of other ) are not permitted whilst on the study other than as pre-medication. During the screening period, doses of up to 20 mg per day may be given but the dose must be reduced to 10 mg/day by Cycle 1 Day 1 (or Day -7 in the CLL combination expansion).
  4. Known or suspected to study drugs.
  5. Cardiac or renal amyloid light-chain (AL) amyloidosis.
  6. Radiotherapy, endocrine therapy, immunotherapy, chemotherapy or medicinal products during the previous 4 weeks before treatment.
  7. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the Sponsor should not exclude the patient.
  8. Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two forms of (one highly effective form plus a barrier method) [oral, injected or implanted hormonal contraception and condom; intra-uterine device and condom; diaphragm with spermicidal gel and condom] or agree to sexual abstinence\^4 for four weeks before entering the trial, during the trial and for twelve months after completing treatment are considered eligible.
  9. Male patients with partners of (unless they agree to take measures not to father children by using a barrier method of contraception [condom plus spermicide] or to sexual abstinence effective from the first administration of BI-1206 or rituximab on the study, throughout the trial and for twelve months afterwards. Men with partners of child-bearing potential must also be willing to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel or sexual abstinence4). Men with pregnant or lactating partners should be advised to use barrier method contraception (e.g. condom plus spermicidal gel) to prevent exposure to the foetus or neonate.
  10. Major thoracic or abdominal surgery from which the patient has not yet recovered.
  11. At high medical risk because of non-malignant systemic disease including infection.
  12. Known to be serologically positive for , or (HIV).
  13. Patients with an active, known or suspected disease (not including CLL auto-immune disease). Patients with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger will be permitted to participate.
  14. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease ( [NYHA]), prior history of cardiac ischaemia or prior history of cardiac arrhythmia.
  15. Patients for whom rituximab is due to severe previous hypersensitivity or any other reason (Arm 2 in Parts A and B [combination arms] only).
  16. Ongoing infection requiring treatment with antibiotics, antifungals or antivirals. Prophylactic use of antibiotics, antifungals or antivirals would not have excluded patients.
  17. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
  18. Is a participant or plans to participate in another interventional clinical study, whilst taking part in this Phase I/IIa study of BI-1206. Participation in an observational study would be acceptable.
  19. Current of other types, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for three years or more and are deemed at negligible risk for recurrence, are eligible for the trial.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Part A: Arm 1: BI-1206 single agent dose escalation phase

    BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).

    Biological: BI-1206 single agent dose escalation phase

  • Experimental
    Part A: Arm 2: Combination of BI-1206 with rituximab escalation phase

    Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).

    Biological: Combination of BI-1206 with rituximab escalation phase

  • Experimental
    Part B: Arm1: BI-1206 single agent expansion phase

    Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.

    Biological: BI-1206 single agent expansion phase

  • Experimental
    Part B: Arm 2: Combination of BI-1206 with rituximab expansion phase

    Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.

    Biological: Combination of BI-1206 with rituximab expansion phase

Interventions

  • BiologicalBI-1206Studies of BI-1206BI-1206 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.

  • BiologicalCombination of BI-1206 with rituximab escalation phase

    An investigation of combination treatment of BI-1206 with rituximab.

  • BiologicalBI-1206Studies of BI-1206BI-1206 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BI-1206 single agent expansion phase at the RP2D.

  • BiologicalCombination of BI-1206 with rituximab expansion phase

    BI-1206 in combination with rituximab at the RP2D.

06

What researchers measure

Primary outcomes

  1. Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206.

    To recommend a dose for future trials with BI-1206 by finding the highest safe dose which can be given to patients.

    Time frame: Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.

  2. Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.

    Establishing the MTD or maximum administered dose MAD of BI-1206 and an anti-CD20 antibody given once weekly for four weeks, via intravenous infusion in patients with relapsed or refractory B-cell malignancies.

    Time frame: Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.

Secondary outcomes

  1. Measurement of PK Parameter Maximum Observed Serum Concentration (Cmax) for BI-1206

    Maximum observed serum concentration after intravenous BI-1206 administration

    Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)

  2. Measurement of PK Parameter Area Under the Serum Concentration-time Curve From Time 0 to the Last Time Point (AUClast) for BI-1206

    Area under the serum concentration-time curve from time 0 to the last time point after intravenous BI-1206 administration.

    Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)

  3. Measurement of PK Parameter Half-life (T1/2) for BI-1206

    BI-1206 half-life after intravenous administration

    Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)

  4. Measurement of PK Parameter Total Body Clearance (CL) for BI-1206

    Total body clearance after intravenous BI-1206 administration

    Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)

  5. Measurement of PK Parameter Volume of Distribution (Vss) for BI-1206

    Volume of distribution after administration of BI-1206

    Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)

  6. Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA

    Patients with true ADA response

    Time frame: Pre dose at weeks 1, 5 and 8, maintenance phase and off-study visit.

  7. Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.

    Number of patients with B-lymphocyte depletion during BI-1206 treatment period.

    Time frame: During induction phase (up to 8 weeks).

  8. Assessment of Best Disease Response According to Criteria for Malignant Lymphoma (Cheson, 2014) Waldenström Macroglobulinaemia Assessment Criteria (Owen 2013, Kimby 2006) or NCI Chronic Lymphocytic Leukaemia (CLL) Criteria (Hallek, 2008).

    To look for signs of anti-tumour activity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies

    Time frame: Response evaluated 4 weeks after last dose in induction phase, every 16 weeks during maintenance phase and at off-study.

  9. Measure Progression Free Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients

    To measure the time to disease progression and twelve month survival

    Time frame: From first BI-1206 administration up to 12 months

  10. Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients

    To measure the time to disease progression and twelve month survival

    Time frame: From first BI-1206 administration up to 12 months. Participants whose last reported status was not death were censored.

07

Results

Posted Jul 8, 2021
Limitations and caveats
The trial was terminated early by the Sponsor based on a strategic decision and not a safety related decision. At the time of trial termination, 14 patients had received BI-1206. No patients received rituximab. As a result of the early termination Part B of the trial did not open.

Participant flow

Trial participants were enrolled at four trial sites between 27 October 2016 and 09 December 2019.

Participant flow — Overall Study
MilestonePart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
Started13100
Completed13100
Not completed0000

Outcome measures

PrimaryDocumenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206.

To recommend a dose for future trials with BI-1206 by finding the highest safe dose which can be given to patients.

Time frame:
Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.
Reported as:
Number · Number of events
Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206.
Number of eventsPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
All AEs28213——
Related AEs21412——
DLT - ALT10——
DLT - AST10——
DLT - infusion related reaction01——
PrimaryDocumenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.

Establishing the MTD or maximum administered dose MAD of BI-1206 and an anti-CD20 antibody given once weekly for four weeks, via intravenous infusion in patients with relapsed or refractory B-cell malignancies.

Time frame:
Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.
Reported as:
Number · BI-1206 MAD (mg)
Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.
BI-1206 MAD (mg)Part A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.100NA——
SecondaryMeasurement of PK Parameter Maximum Observed Serum Concentration (Cmax) for BI-1206

Maximum observed serum concentration after intravenous BI-1206 administration

Time frame:
Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Reported as:
Median · ng/mL
Measurement of PK Parameter Maximum Observed Serum Concentration (Cmax) for BI-1206
ng/mLPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
0.4 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation)6075 (31.2 to 13100)———
100 mg BI-1206 (Cohort 2) Dose 115600 (6990 to 19300)———
100 mg BI-1206 (Cohort 2) Dose 412700 (8850 to 22500)———
SecondaryMeasurement of PK Parameter Area Under the Serum Concentration-time Curve From Time 0 to the Last Time Point (AUClast) for BI-1206

Area under the serum concentration-time curve from time 0 to the last time point after intravenous BI-1206 administration.

Time frame:
Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Reported as:
Median · h*ng/mL
Measurement of PK Parameter Area Under the Serum Concentration-time Curve From Time 0 to the Last Time Point (AUClast) for BI-1206
h*ng/mLPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
0.4 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation)76100 (9.1 to 384000)———
100 mg BI-1206 (Cohort 2) Dose 1462000 (129000 to 594000)———
100 mg BI-1206 (Cohort 2) Dose 4193000 (168000 to 733000)———
SecondaryMeasurement of PK Parameter Half-life (T1/2) for BI-1206

BI-1206 half-life after intravenous administration

Time frame:
Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Reported as:
Median · h
Measurement of PK Parameter Half-life (T1/2) for BI-1206
hPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose)NA (NA to NA)———
10 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation)17.3 (9.3 to 18.9)———
100 mg BI-1206 (Cohort 2) Dose 116 (11.5 to 21.6)———
100 mg BI-1206 (Cohort 2) Dose 412.1 (10.8 to 46.6)———
SecondaryMeasurement of PK Parameter Total Body Clearance (CL) for BI-1206

Total body clearance after intravenous BI-1206 administration

Time frame:
Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Reported as:
Median · mL/h/kg
Measurement of PK Parameter Total Body Clearance (CL) for BI-1206
mL/h/kgPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose)NA (NA to NA)———
10 - 50 mg BI-1206 (Cohort 1 intra patient dose escalation)6.34 (2.45 to 10.8)———
100 mg BI-1206 (Cohort 2) Dose 13.32 (1.82 to 9.63)———
100 mg BI-1206 (Cohort 2) Dose 47.44 (6.61 to 8.64)———
SecondaryMeasurement of PK Parameter Volume of Distribution (Vss) for BI-1206

Volume of distribution after administration of BI-1206

Time frame:
Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Reported as:
Median · mL/kg
Measurement of PK Parameter Volume of Distribution (Vss) for BI-1206
mL/kgPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose)NA (NA to NA)———
10 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation)84.2 (60.6 to 208)———
100 mg BI-1206 (Cohort 2) Dose 181.0 (50.5 to 182)———
100 mg BI-1206 (Cohort 2) Dose 4126 (124 to 143)———
SecondaryMeasurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA

Patients with true ADA response

Time frame:
Pre dose at weeks 1, 5 and 8, maintenance phase and off-study visit.
Reported as:
Count of participants · Participants
Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA
ParticipantsPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA00——
SecondaryMeasurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.

Number of patients with B-lymphocyte depletion during BI-1206 treatment period.

Time frame:
During induction phase (up to 8 weeks).
Reported as:
Count of participants · Participants
Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.
ParticipantsPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.00——
SecondaryAssessment of Best Disease Response According to Criteria for Malignant Lymphoma (Cheson, 2014) Waldenström Macroglobulinaemia Assessment Criteria (Owen 2013, Kimby 2006) or NCI Chronic Lymphocytic Leukaemia (CLL) Criteria (Hallek, 2008).

To look for signs of anti-tumour activity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies

Time frame:
Response evaluated 4 weeks after last dose in induction phase, every 16 weeks during maintenance phase and at off-study.
Reported as:
Count of participants · Participants
Assessment of Best Disease Response According to Criteria for Malignant Lymphoma (Cheson, 2014) Waldenström Macroglobulinaemia Assessment Criteria (Owen 2013, Kimby 2006) or NCI Chronic Lymphocytic Leukaemia (CLL) Criteria (Hallek, 2008).
ParticipantsPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
Stable disease30——
Progressive disease70——
Not evaluable31——
SecondaryMeasure Progression Free Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients

To measure the time to disease progression and twelve month survival

Time frame:
From first BI-1206 administration up to 12 months
Reported as:
Count of participants · Participants
Measure Progression Free Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients
ParticipantsPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
Progression free & alive20——
Progressed, died or unknown111——
SecondaryMeasure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients

To measure the time to disease progression and twelve month survival

Time frame:
From first BI-1206 administration up to 12 months. Participants whose last reported status was not death were censored.
Reported as:
Mean · Days
Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients
DaysPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients152.2 (38 to 360)———

Adverse events

Collected over Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI 1206 or rituximab. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase1/13 (7.7%)10/13 (76.9%)13/13 (100%)
Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase0/1 (0%)1/1 (100%)1/1 (100%)
Part B: Arm1: BI-1206 Single Agent Expansion Phase———
Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase———
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
Infusion related reactionInjury, poisoning and procedural complications5/131/1——
PneumoniaInfections and infestations2/130/1——
Pleural effusionRespiratory, thoracic and mediastinal disorders2/130/1——
Atrial fibrillationCardiac disorders1/130/1——
Abdominal painGastrointestinal disorders1/130/1——
DiarrhoeaGastrointestinal disorders1/130/1——
Non-cardiac chest painGeneral disorders1/130/1——
Abdominal abscessInfections and infestations1/130/1——
Lower respiratory tract infectionInfections and infestations1/130/1——
Metapneumovirus infectionInfections and infestations1/130/1——
Most frequent other events
Showing 10 of 82
Most frequent other events
EventPart A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase
TachycardiaCardiac disorders4/131/1——
Infusion related reactionInjury, poisoning and procedural complications9/131/1——
Alanine aminotransferase increasedInvestigations2/131/1——
Aspartate aminotransferase increasedInvestigations1/131/1——
Platelet count decreasedInvestigations2/131/1——
HyperglycaemiaMetabolism and nutrition disorders1/131/1——
DyspnoeaRespiratory, thoracic and mediastinal disorders1/131/1——
UrticariaSkin and subcutaneous tissue disorders8/131/1——
HypotensionVascular disorders6/131/1——
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/131/1——

Baseline characteristics

Trial terminated before opening Part B.

Age, Categorical
Age, Categorical(Participants)Part A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion PhaseTotal
<=18 years00——0
Between 18 and 65 years51——6
>=65 years80——8
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion PhaseTotal
Female51——6
Male80——8
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Part A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion PhaseTotal
Count of participants————0
Region of Enrollment
Region of Enrollment(participants)Part A: Arm 1: BI-1206 Single Agent Dose Escalation PhasePart A: Arm 2: Combination of BI-1206 With Rituximab Escalation PhasePart B: Arm1: BI-1206 Single Agent Expansion PhasePart B: Arm 2: Combination of BI-1206 With Rituximab Expansion PhaseTotal
United Kingdom131——14
08

Study locations

5 sites
  • Leicester Royal Infirmary
    Leicester, England LE1 5WW, United Kingdom
  • Christie Hospital
    Manchester, England M20 4BX, United Kingdom
  • Oxford Cancer and Haematology Centre, Churchill Hospital
    Oxford, England OX3 7LE, United Kingdom
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, S016 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Mar 2020, 40 months.

Results were first posted in Jul 2021, 1 year 3 months after primary completion.

Of 52 non-industry phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 82. This study's 40 months is below that.

Counting every sponsor, half of 94 studies reached it within 71 months; a quarter within 55 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2016
First posted
Oct 14, 2016
StartActual
Oct 27, 2016
Primary completionActual
Mar 19, 2020
CompletionActual
Mar 19, 2020
Results first posted
Jul 8, 2021
Last update
Jul 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02933320
Lead sponsor
Cancer Research UK
Collaborators
BioInvent International AB, Bloodwise
Responsible party
Sponsor
First posted
Oct 14, 2016
Start date
Oct 27, 2016
Primary completion
Mar 19, 2020
Completion
Mar 19, 2020
Results posted
Jul 8, 2021
Last update
Jul 8, 2021

Study contacts

Andrew Davies, Prof
principal investigator · University of Southampton

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI-1206

Start the discussion